Replimune Group, Inc. - Common Stock (REPL)

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) common stock between October 20, 2025 and April 10, 2026, inclusive (“the Class Period”).

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at an offering price of $12.06 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,736,340 shares of its common stock at a purchase price of $12.0599 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering are to be sold by Replimune. The offering is expected to close on August 11, 2026, subject to the satisfaction of customary closing conditions.

The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the “Class Period”).

Law Offices of Howard G. Smith reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the “Class Period”).

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 inclusive (the “Class Period”).

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the “Class Period”). Replimune investors have until October 5, 2026 to file a lead plaintiff motion.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the “Class Period”). Replimune investors have until October 5, 2026 to file a lead plaintiff motion.

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company’s lead product candidate is RP1 (vusolimogene oderparepvec).

Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the District of Massachusetts, captioned Toor v. Replimune Group, Inc. et al., Case No. 1:26-cv-13612, on behalf of persons and entities that purchased or otherwise acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Broad label to address high unmet need in advanced melanoma

If you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) on behalf of investors concerning the Company’s possible violations of federal securities laws.

WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.

FDA decision expected by August 2, 2026

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting.

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting.